IperionX (NASDAQ:IPX) Chairman Purchases 225,000 Shares

IperionX Limited Sponsored ADR (NASDAQ:IPXGet Free Report) Chairman Todd Hannigan acquired 225,000 shares of the stock in a transaction on Friday, July 10th. The stock was bought at an average price of $3.58 per share, with a total value of $805,500.00. Following the transaction, the chairman directly owned 26,333,334 shares of the company’s stock, valued at approximately $94,273,335.72. The trade was a 0.86% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Todd Hannigan also recently made the following trade(s):

  • On Monday, July 13th, Todd Hannigan acquired 300,000 shares of IperionX stock. The shares were bought at an average cost of $3.59 per share, with a total value of $1,077,000.00.
  • On Tuesday, April 28th, Todd Hannigan bought 220,000 shares of IperionX stock. The stock was purchased at an average price of $4.48 per share, for a total transaction of $985,600.00.
  • On Wednesday, April 29th, Todd Hannigan bought 260,000 shares of IperionX stock. The stock was purchased at an average cost of $4.20 per share, for a total transaction of $1,092,000.00.

IperionX Price Performance

NASDAQ:IPX opened at $25.03 on Monday. The company has a fifty day moving average of $34.28 and a 200 day moving average of $37.50. IperionX Limited Sponsored ADR has a 52 week low of $21.66 and a 52 week high of $61.45. The company has a current ratio of 4.03, a quick ratio of 4.00 and a debt-to-equity ratio of 0.03.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on IPX shares. Alliance Global Partners restated a “buy” rating on shares of IperionX in a research report on Tuesday, April 28th. Roth Capital reissued a “buy” rating on shares of IperionX in a research note on Monday, June 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of IperionX in a research note on Tuesday, April 21st. Finally, BTIG Research boosted their price target on IperionX from $40.00 to $55.00 and gave the company a “buy” rating in a report on Friday, June 5th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $60.33.

Read Our Latest Report on IperionX

Institutional Trading of IperionX

Several large investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its holdings in IperionX by 40.3% in the second quarter. GAMMA Investing LLC now owns 1,681 shares of the company’s stock valued at $50,000 after acquiring an additional 483 shares in the last quarter. JPMorgan Chase & Co. bought a new position in IperionX in the 2nd quarter worth $66,000. State of Tennessee Department of Treasury purchased a new stake in shares of IperionX in the 4th quarter worth about $119,000. Quadrature Capital Ltd lifted its position in shares of IperionX by 42.8% in the 4th quarter. Quadrature Capital Ltd now owns 14,918 shares of the company’s stock worth $540,000 after purchasing an additional 4,471 shares during the period. Finally, DV Equities LLC bought a new stake in shares of IperionX during the 4th quarter valued at about $178,000. Institutional investors own 2.76% of the company’s stock.

About IperionX

(Get Free Report)

IperionX (NASDAQ: IPX) is a mineral technology company focused on the production and commercialization of high‐purity titanium and zirconium products. The company’s core activities include the development of advanced mineral sands projects and the deployment of proprietary processing technologies aimed at supplying feedstocks to aerospace, defense, additive manufacturing and battery markets.

At the heart of IperionX’s operations is the Stony Creek Project in Virginia, where the company holds significant mineral sands rights.

Recommended Stories

Receive News & Ratings for IperionX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IperionX and related companies with MarketBeat.com's FREE daily email newsletter.